Should You Hold Crinetics Pharmaceuticals (CRNX)?

The Pgim Jennison Health Sciences Fund released the investor’s speech in the first quarter of 2025. A copy of the message can be downloaded here. The S&P 1500 health care index returned by 5.5 % in the first quarter, outperforing the S&P 500 -4.3 % return. Health care services and services exceeded the index in performance during this quarter. Medicines, healthcare technology and mediach have witnessed gains, but the indicator lagged. On the contrary, life science tools and services decreased during the same period. During the quarter, the fund witnessed a loss of value, which led to the weak index. The choice of stocks in biotechnology was the main cause of the fully proportional performance. The choice of stocks in medicines was another relative field. While the choice of shares in the providers of health care, biotechnology and lack of weight in life science tools and services contribute to the best relative results. In addition, please check the five best holdings of the box to know its best choices in 2025.

In the investor speech in the first quarter of 2025, the Pgim Jennison Health Sciences such as Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX). Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a medicine company in the clinical stage. The return of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) -12.15 %, and its shares have lost 39.75 % of its value over the past 52 weeks. On July 7, 2025, Crinetics Pharmaceuticals closed, Inc.

Pgim Jennison Health Sciences Fund is following the following in terms of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) in the investor’s speech in the first quarter 2025:

“Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is a biotechnology company for the clinical stage that focuses on developing small oral molecules for endocrine indicators. Their leading origins are Paltusotine, Nahed ST2 (SST2) orally soluble (SST2) in development for the appearance of brains and cancer syndrome. The company has completed its central experiences in Acromegaly and has a history of prescribed drug users (PDUFA) specified on 9/25/25 and also plans to start a pivotal study of the third stage in cancer syndrome soon. The second assets of the company, ATUMELNANAN, which is an ACTH, is under development of congenital adrenal enlargement (CAH) and Kushing disease. In June 2024, the company provided temporary data for Atuelnant in both indicators with amazing results, which led to a great appreciation of shares during the rest of 2024. In January 2025, the company reported the full data of the study of the 2 CAH. Here we have seen a decrease in the event from lowering the initial data and showed high liver enzymes, which led to the sale of stocks. We believe that the sales process has been affected by the decrease in effectiveness in non -compliance, which can be resolved in the third stage experience, and it appears that one of the liver enzyme heights is not associated with atumelnant. The ongoing open stickers extension will clarify the safety file from the Atuelnant. The company lacks large clinical data stimuli this year, but we expect the stock to be able to gradually estimate over time as we get more colors on Atumelnant and get updates from the previous stage pipeline in Crinetics. “